Peptide Knowledge Base · Sexual Health
PT-141: what it is, what the evidence says, and its real status
An FDA-approved peptide (as Vyleesi) that raises sexual desire by acting on the brain's arousal pathways, not blood flow.
Short version: the one genuinely FDA-approved desire-side peptide, but only as the branded drug Vyleesi, and only for premenopausal women with HSDD. We don't offer it. This page is the honest education so you can take it to a clinician.
Can you actually get it?
Plain-English verdict: Education only.
Regulatory status: FDA-approved as Vyleesi (2019) · Approved 2019.
We don't offer PT-141. It's FDA-approved only as the branded drug Vyleesi (bremelanotide), and only for premenopausal women with acquired, generalized HSDD, a real, legitimate option, just not one in our catalog. Compounded 'PT-141' is a separate, non-FDA-approved route. We educate here and route you to the Knowledge Base; we make no availability promise and show no price.
How does PT-141 work?
A melanocortin (MC3R/MC4R) receptor agonist, bremelanotide, acting on central arousal pathways in the brain rather than on blood flow.
What it does — and what it does not do
What it does: Has genuine FDA-approved evidence for one specific use, raising sexual desire in premenopausal women with acquired, generalized HSDD, by working centrally rather than on blood flow.
What it does not do: It is not approved for men or for postmenopausal women (those uses are off-label), it is not a blood-flow 'ED pill,' and it is not something we offer. Branded Vyleesi and compounded bremelanotide are different regulatory things.
How honest is the evidence?
Evidence grade A — randomized phase-3 trials (RECONNECT) behind the approved product, bremelanotide / Vyleesi. Read our grading methodology for what each grade means.
What we still don't know: Formal efficacy and approval in men aren't established; long-horizon repeated-use effects aren't well characterized. Response and tolerability vary, with nausea and transient blood-pressure changes reported.
WADA status: Not prohibited.
How it is taken
What the literature reports for the approved product: as-needed subcutaneous, ahead of activity. Educational only, no dose figures, never an instruction to self-administer.
Who should not take it
Uncontrolled hypertension or known cardiovascular disease. Clinician evaluation required.
Sources
Clayton et al., bremelanotide (PT-141) RECONNECT trials, Obstet Gynecol 2019 · FDA approval of Vyleesi (bremelanotide), June 2019 · FDA labeling (Vyleesi)
Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker or the knowledge base.
Last reviewed 2026-08-11 · Peptós.LIFE · Not medical advice.